Welcome to our dedicated page for Citius Oncology news (Ticker: CTOR), a resource for investors and traders seeking the latest updates and insights on Citius Oncology stock.
Citius Oncology, Inc. (Nasdaq: CTOR) generates a steady flow of news centered on its role as a platform for developing and commercializing novel targeted oncology therapies. Most recent company updates focus on LYMPHIR™ (denileukin diftitox-cxdl), an IL‑2 receptor-directed fusion protein approved by the FDA for adult patients with relapsed or refractory Stage I–III cutaneous T‑cell lymphoma (CTCL) after at least one prior systemic therapy.
News coverage for CTOR frequently highlights key milestones in the commercial rollout of LYMPHIR. Company press releases describe the U.S. commercial launch of LYMPHIR, the transition from a pre‑revenue to a revenue-generating profile, and the completion of distribution agreements with the three leading U.S. pharmaceutical wholesalers, including a distribution services agreement with McKesson Corporation. These items explain how Citius Oncology aims to make LYMPHIR available to major medical centers, specialized hospitals, community oncology practices, and infusion centers.
Investors following CTOR can also expect updates on international access initiatives. Citius Oncology reports that it has secured access to LYMPHIR in 19 markets outside the United States via regional partners and Named Patient Programs, as well as exclusive distribution agreements in territories such as Turkey and certain Gulf Cooperation Council countries. Such announcements provide insight into the company’s global access strategy for CTCL patients.
Additional CTOR news items cover strategic financings, including registered direct offerings and private placements intended to support the LYMPHIR launch and general corporate purposes, as well as collaborations with technology partners like Verix to deploy AI-powered commercial optimization tools. Regulatory and corporate developments, such as SEC filings, proxy statements, and annual meeting results, also appear in the news flow. For a consolidated view of these earnings updates, commercialization milestones, financing transactions, and partnership announcements, the CTOR news page offers a single reference point that can be revisited as new disclosures are released.
Citius Pharmaceuticals and its subsidiary Citius Oncology announced preparations for the commercial launch of LYMPHIR™ in the first half of 2025. LYMPHIR, approved in August 2024, is an immunotherapy treatment for adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL).
The companies have made significant progress in key launch areas including: securing commercial supply agreements and producing first-year launch supply; implementing healthcare provider education programs; working on reimbursement pathways; submitting for a unique J-code; securing inclusion in NCCN guidelines; developing patient assistance programs; and building a specialized sales team.
Management is also exploring additional growth opportunities through international licensing partnerships and potential expanded indications for LYMPHIR, including its use as a combination immunotherapy.
Citius Oncology (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals (Nasdaq: CTXR), has engaged Jefferies as its exclusive financial advisor to explore strategic alternatives for maximizing shareholder value. The company is considering various options including partnerships, joint ventures, mergers, acquisitions, and licensing transactions.
The announcement comes as Citius Oncology prepares to launch LYMPHIR™, their recently FDA-approved therapy for treating patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) who have undergone at least one prior systemic therapy.
The company has not established a specific timeline for this strategic review process and will only disclose developments if the Board of Directors approves a specific transaction or deems disclosure necessary. There is no guarantee that this process will result in any strategic transaction.
Citius Pharmaceuticals (CTXR) reported fiscal year 2024 results, highlighting key achievements including FDA approval of LYMPHIR™ for CTCL treatment and positive Phase 3 trial results for Mino-Lok®. The company reported cash and equivalents of $3.3 million as of September 30, 2024. Financial results show R&D expenses decreased to $11.9 million from $14.8 million, while G&A expenses increased to $18.2 million from $15.3 million. Net loss widened to $39.4 million ($5.97 per share) compared to $32.5 million ($5.57 per share) in 2023. The company completed merger of its oncology subsidiary to form Citius Oncology (CTOR) and plans LYMPHIR commercial launch in first half of 2025.
Citius Oncology (NASDAQ: CTOR) reported its fiscal year 2024 results and key developments. The company achieved FDA approval for LYMPHIR™, an immunotherapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL), and began trading on Nasdaq under CTOR in August 2024. The company is preparing for LYMPHIR's commercial launch in H1 2025, including manufacturing inventory and initiating sales force recruitment.
Financial results showed R&D expenses of $4.9M (up from $4.2M in 2023), G&A expenses of $8.1M (up from $5.9M), and stock-based compensation of $7.5M (up from $2.0M). Net loss widened to $21.1M ($0.31 per share) compared to $12.7M ($0.19 per share) in 2023.
Citius Pharmaceuticals and Citius Oncology announced preliminary results from a Phase I trial evaluating the combination of pembrolizumab (KEYTRUDA®) and LYMPHIR™ in patients with recurrent solid tumors, focusing on gynecological cancers like ovarian, endometrial, and cervical. The trial showed a 27% Objective Response Rate (ORR) and a 33% Clinical Benefit Rate (CBR) with a median Progression-Free Survival (PFS) of 57 weeks. The regimen was well-tolerated, with no serious immune-related adverse events. The study, nearing completion, will enroll three more patients. The results suggest LYMPHIR may enhance the efficacy of immune checkpoint inhibitors like pembrolizumab. The trial's promising outcomes support expanding research into a Phase II study to evaluate the combination's benefits across a broader range of solid tumors.
Citius Pharmaceuticals (CTXR) announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York City. CEO Leonard Mazur will present on September 10, 2024, at 9:00 am ET at the Lotte New York Palace Hotel and host one-on-one investor meetings.
Key business developments to be discussed include:
- FDA approval of LYMPHIR™ for cutaneous T-cell lymphoma treatment
- Merger of a subsidiary with TenX Keane, forming Citius Oncology (CTOR)
- Successful Phase 3 Pivotal Trial of Mino-Lok®, an antibiotic lock solution for catheter-related bloodstream infections
Investors can register on the conference website and join the live webcast presentation.
Citius Pharmaceuticals (Nasdaq: CTOR) will participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York City on September 9–11, 2024.
Chairman and CEO Leonard Mazur will present at 9:00 am ET on Tuesday, September 10, 2024 and host one-on-one investor meetings; the presentation may be webcast and timing is subject to change.
Mr. Mazur plans to discuss three recent developments: FDA approval of LYMPHIR™ (denileukin diftitox-cxdl) for CTCL, the merger of a subsidiary with TenX Keane to form publicly listed Citius Oncology (Nasdaq: CTOR), and that the Phase 3 pivotal trial of Mino-Lok achieved primary and secondary endpoints.
Citius Pharmaceuticals and Citius Oncology announced that LYMPHIR™ has been added to the NCCN Clinical Practice Guidelines in Oncology with a Category 2A recommendation. This inclusion supports LYMPHIR as an appropriate treatment option for patients with Cutaneous T-cell Lymphoma (CTCL) who have undergone at least one prior systemic therapy.
LYMPHIR, a novel immunotherapy targeting the interleukin-2 receptor on malignant T-cells and Tregs, was recently approved by the FDA based on results from the Phase 3 Pivotal Study 302. The addition to NCCN Guidelines is expected to facilitate adoption and ease reimbursement, particularly for patients eligible for CMS coverage.
Citius Pharmaceuticals (CTXR) reported fiscal Q3 2024 results and key developments:
- FDA approval of LYMPHIR™ for cutaneous T-cell lymphoma treatment
- Completed merger of oncology subsidiary with TenX Keane; Citius Oncology (CTOR) to start trading on Nasdaq
- Achieved primary and secondary endpoints in Mino-Lok® Phase 3 Trial
- $17.9 million cash as of June 30, 2024
- Net loss of $10.6 million ($0.06 per share) for Q3, compared to $8.5 million ($0.06 per share) in Q3 2023
- R&D expenses decreased to $2.8 million from $3.8 million year-over-year
- G&A expenses increased to $4.8 million from $3.7 million year-over-year
CEO Leonard Mazur highlighted the FDA approval of LYMPHIR and successful Mino-Lok trial as key milestones.